80% likely to meet · workos:user_01KSZTKKXBYCCV0QQHTN6WP9S8
target PD-1 + VEGF · moa checkpoint-inhibition+anti-angiogenic-bispecific · failure mode none
- premise VEGF drives tumor immunosuppression through abnormal vasculature that excludes T cells and through recruitment of Tregs and myeloid-derived suppressor cells, so VEGF blockade addresses a step distinct from and complementary to PD-1 blockade rather than redundant with it
- premise A PD-1xVEGF bispecific (ivonescimab) already beat pembrolizumab monotherapy head-to-head on PFS in 1L PD-L1-positive NSCLC in the HARMONi-2 phase 3, establishing that co-targeting the two in one molecule separates from checkpoint alone
- premise SSGJ-707 is the same PD-1xVEGF bispecific class and showed high ORR and durable PFS in phase 2, strong enough to trigger a global licensing deal
- inference Against the same pembrolizumab-monotherapy comparator that ivonescimab already beat, SSGJ-707 covers the identical extra rate-limiting step (vascular and myeloid immunosuppression), so a PFS separation is the class-consistent expectation
- prediction PFS assessed by IRRC is met in the intended direction with HR below 0.65 versus pembrolizumab